In 2016, we performed the Chinese PK Study involving Chinese patients who are domiciled in the United States. We enrolled 66 patients in this study, consisting of two parts. In part A, 32 subjects received a single escalating dose; Part B enrolled 34 subjects which received a multiple escalating dose. Dr. Evelyn Darius served as the Study Investigator. No safety signal was identified in this study and we deemed no changes were required in the enrollment of Chinese patients into the ARREST Study. Moreover, having this Chinese PK Study data may give us a head start in future licensing discussions with potential Chinese partners for the development of Aramchol in China.

In terms of your suggestions Paul, I’m afraid we can’t separate intermittent fasting benefits from CR, and IGF is too intertwined with MTOR for us to be confident benefits would be additive. I regard angiotensin treatment as mainly benefiting mitochondria. So it probably wouldn’t sum if you’re already doing NR or something like that.

Pan, D., Zhe, X., Jakkaraju, S., Taylor, G. A. & Schuger, L. P311 induces a TGF-beta1-independent, nonfibrogenic myofibroblast phenotype. The Journal of clinical investigation. 110, 1349–1358 (2002).

Tang, Y. et al. Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats. Phytomedicine 18, 1024–1030, 10.1016/j.phymed.2011.05.007 (2011).

Assuming that they have the funding for their clinical trial, I am wondering what could be the schedule. I would think: 2018: phase 0 (animal model) 2019: phase 1 2020-2022: phase 2 (is 2 years reasonable?)

In the business segment research chemicals (which accounts for 20% of Bachem’s sales revenue) Bachem offers peptide custom synthesis and products that are marketed through the Bachem catalogs, containing more than 9000 products available from stock.

Humans are by far an incredibly unique species in the known universe. Which is why we should be cautious before any conclusive assumption that 200 years can never be crossed. At this vantage it may seem so but if an Egyptian scholar or an Indian Rishi 2,000 years ago said that one day humans will communicate across the world within seconds telepathically their peers must have surely mocked them but today we take this for granted. We have what is called in Sanskrit ‘Brahmastra’ the ultimate weapon: the ability to manipulate matter. This can create unthinkable opportunities. For example we can create nanobots powered by solar radiation mining nearby planets which can build millions of nanobots like bacterial multiplication which would then work from trillion different points to create another planet in our orbit based on a design mesh. This sounds absolutely crazy today but to me it’s absolutely possible. Our biology is a finite system and a finite system can be mastered one day. This is biggest incentive of a long life the wondrous amazement if seeing mind boggling technologies being revealed/discovered.

        PNH is a rare, chronic, life-threatening blood disorder where red blood cells are mistakenly attacked and destroyed by the complement system. In the second quarter of 2017, we initiated a Phase 2 clinical trial evaluating zilucoplan in PNH patients, and in February 2018, we completed dosing and announced positive top-line data from this trial. During the second and third quarter of 2018, we

Undesirable side effects caused by Aramchol could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or applicable foreign regulatory authorities. To date, we have completed six clinical trials of Aramchol, one proof of concept study in patient with gallstones, and a Phase 2a, investigator initiated clinical trial.

Option 2. Don’t love it, but I guess in the context of getting first to 105 and then 10 bad years, maybe. I don’t like the headline: ” He died at 110 frail, sickly, and miserable, but he made it”

Fan, J. M. et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney international. 56, 1455–1467 (1999).

Very interesting, thanks for that – I was not aware of that blog, or of the connection between AMPK and telomeres via TERRA.